Metagenomi, Inc. (MGX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Metagenomi reported revenue of $25.2M, down 51.8% from $52.3M the year before. Net income was -$87.9M (a -348.5% net margin), or -$2.36 per diluted share. Operating margin was -380.9%. Operating activities generated -$88.9M of cash, leaving -$89.5M of free cash flow. At fiscal year end, Metagenomi held $221.1M in total assets against $62.5M in total liabilities, including $41.7M of cash and equivalents.
Open the full interactive Metagenomi financials → Quarterly statements, key ratios, valuation history and price charts.
Metagenomi Key Stats
| Share Price | $0.92 |
|---|---|
| Market Cap | $34.5M |
| Revenue YoY Growth | -51.8% |
| 52-Week Range | $0.92 – $3.35 |
| Shares Outstanding | 37.7 million (basic, 2026 Q2) |
Metagenomi Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $52.3M | $25.2M |
| Operating Income | -$88.9M | -$96.0M |
| Pre-Tax Income | -$83.6M | -$87.9M |
| Income Tax | -$5.5M | -$58,000 |
| Net Income | -$78.1M | -$87.9M |
| Diluted EPS | -$2.36 | -$2.36 |
Metagenomi Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $8.7M | $3.9M | $1.2M | $0 |
| Net Income | -$20.4M | -$22.5M | -$23.1M | -$27.5M |
| Diluted EPS | -$0.55 | -$0.60 | -$0.61 | -$0.73 |
Metagenomi Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $27.4M | $41.7M |
| Current Assets | $258.0M | $165.5M |
| Total Assets | $324.6M | $221.1M |
| Current Liabilities | $37.3M | $22.9M |
| Total Liabilities | $89.7M | $62.5M |
| Shareholders' Equity | $234.9M | $158.6M |
Metagenomi Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$109.1M | -$88.9M |
| Cash From Investing | -$88.2M | $103.5M |
| Cash From Financing | $84.0M | -$356,000 |
| Free Cash Flow | -$112.2M | -$89.5M |
Figures from Metagenomi's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Metagenomi financials page for every line item.
Metagenomi Company Profile
| Ticker | MGX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Emeryville, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001785279 |
Frequently Asked Questions
What was Metagenomi's revenue in fiscal 2025?
Metagenomi (MGX) reported revenue of $25.2M for fiscal 2025.
What was Metagenomi's net income in fiscal 2025?
Metagenomi reported net income of -$87.9M for fiscal 2025.
What was Metagenomi's earnings per share (EPS) in fiscal 2025?
Metagenomi's diluted EPS was -$2.36 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Metagenomi generate in fiscal 2025?
Metagenomi generated -$89.5M of free cash flow in fiscal 2025.
What was Metagenomi's revenue last quarter?
In its most recent reported quarter (2026 Q2), Metagenomi reported revenue of $0.
How many shares of Metagenomi are outstanding?
Metagenomi reported a weighted average of 37.7 million basic shares outstanding in 2026 Q2.
What is Metagenomi's market cap?
Based on its latest closing price, Metagenomi (MGX) has a market capitalization of about $34.5M.
When does Metagenomi's fiscal year end?
Metagenomi's fiscal year end, as registered with the SEC, is December 31.
Where is Metagenomi headquartered?
Metagenomi lists its business address in Emeryville, California in its SEC filings.
Metagenomi Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →